GenInvo provides a unique combination of expertise in Life sciences, Leading-edge Technologies and Software development, enabling us to provide truly Innovative and Transformative Products, Solutions and Services.
We at GenInvo see the Impact of Innovation up close on a daily basis from our client’s perspective. We strive to develop efficient, innovative products and solutions for our clients to make the drug development process smarter, faster, and more cost effective.
For most of our clients, Innovation is the essential element of their corporate mission and success. GenInvo supports our clients in their journey, working collaboratively to understand the needs of their systems, processes and their current challenges within these areas.
Geninvo has a strong pipeline of Innovative products built using advanced technologies to support the unmet gaps and have launched state-of-the-art products such as Shadow and DocQC. We are continuing to build new, robust, innovative products. ApoGI, is an example of an integrated automation platform that leverages AI (artificial intelligence) and ML (machine learning) to focus on standards in metadata management to streamline processes, and the generation of artefacts typically associated with the clinical study lifecycle.
Standing strong with Community
In these trying times, the GenInvo team is ensuring school kids don’t go hungry. In our hometown, there are many kids who depend on schools for providing their lunch, for free, every day. With the schools being closed due to the ongoing crisis (COVID-19 Coronavirus), the GenInvo team gave away several hundred lunch packets to a nearby school.
If you are in Bloomingtion/Normal (IL) area, and if you read this message, please make sure to reach out to your nearby schools and find out how each one of you can help.
GenInvo is taking steps to keep our employees safe while continuing to serve our customers. In response to concerns about the spread of COVID-19 Coronavirus, we are implementing social distancing in the workplace and instructing employees who can, to work from home.
COVID-19 is a disease caused by a specific virus (SARS-CoV-2) and labeled in the press “coronavirus” or “novel coronavirus.”
Much about the disease is not currently known. While public health officials are still determining the medical impacts of the virus along with certain key characteristics, such as the incubation period, we believe the economic impact will in part depend on how the public reacts to the virus. Public reaction could allow the disease to spread more quickly and widely, or it could create unnecessary costs.